Task C1: A Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose Phase 1 Study of SARS-CoV-2 Therapeutics

NIH RePORTER · NIH · N01 · $245,549 · view on reporter.nih.gov ↗

Abstract

The Early Phase Clinical Trial Units provide a vehicle for investigation of new agents in the treatment and prevention of infectious diseases and can carry out all aspects of interventional clinical trial implementation.

Key facts

NIH application ID: 11202302
Project number: 75N93022D00016-P00002-759302300001-2
Recipient: DYNPORT VACCINE COMPANY, LLC
Principal Investigator: CASEY LONG
Activity code: N01
Funding institute: NIH
Fiscal year: 2024
Award amount: $245,549
Award type: —
Project period: 2023-05-15 → 2024-10-07